Fidson Healthcare Limited, a wholly indigenous pharmaceutical company, is a member of the Fidson Group, with corporate Head Office in Lagos and manufacturing plant in Ota, both in Nigeria. The company, which was formed in 1995; manufactures markets and exports high quality pharmaceutical products in accordance with WHO/GMP, laid down standards.
ÃƒÆ’Ã†â€™Ãƒâ€ Ã¢â‚¬â„¢ÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€¦Ã‚Â¡ÃƒÆ’Ã†â€™ÃƒÂ¢Ã¢â€šÂ¬Ã…Â¡ÃƒÆ’Ã¢â‚¬Å¡Ãƒâ€šÃ‚Â· Fidson has been very prominent in the Nigerian pharmaceutical industry since its entry. It attained a significant height in the industry when it emerged the first indigenous pharmaceutical company to manufacture anti-retroviral drug. The drug, known as Virex Anti-retroviral, was 100% formulated and manufactured in Nigeria.
ÃƒÆ’Ã†â€™Ãƒâ€ Ã¢â‚¬â„¢ÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€¦Ã‚Â¡ÃƒÆ’Ã†â€™ÃƒÂ¢Ã¢â€šÂ¬Ã…Â¡ÃƒÆ’Ã¢â‚¬Å¡Ãƒâ€šÃ‚Â· Fidson also displays outstanding performance records. Its compounded annual growth rates (CAGR) in turnover and after-tax profit have been 44.2% and 46.7% respectively. Similarly, the company has consistently paid dividend in each past financial year. At its last financial year ended June 30, 2007; the company declared and paid a dividend of N2.27 in addition to a bonus issue of 2 for 1 Ordinary share held by the existing shareholders. As at date, the company still has over N800 million as distributable reserves.
ÃƒÆ’Ã†â€™Ãƒâ€ Ã¢â‚¬â„¢ÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€¦Ã‚Â¡ÃƒÆ’Ã†â€™ÃƒÂ¢Ã¢â€šÂ¬Ã…Â¡ÃƒÆ’Ã¢â‚¬Å¡Ãƒâ€šÃ‚Â· As part of efforts to finance its growth and diversification plans, Fidson Healthcare Limited is planning to raise about N2.1 billion from the Nigerian Capital Market by privately placing 540 million Ordinary shares of 50k at a price of N3.95 each.
ÃƒÆ’Ã†â€™Ãƒâ€ Ã¢â‚¬â„¢ÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€¦Ã‚Â¡ÃƒÆ’Ã†â€™ÃƒÂ¢Ã¢â€šÂ¬Ã…Â¡ÃƒÆ’Ã¢â‚¬Å¡Ãƒâ€šÃ‚Â· MeristemÃƒÆ’Ã†â€™Ãƒâ€ Ã¢â‚¬â„¢ÃƒÆ’Ã¢â‚¬Å¡Ãƒâ€šÃ‚Â¢ÃƒÆ’Ã†â€™Ãƒâ€šÃ‚Â¢ÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€¦Ã‚Â¡ÃƒÆ’Ã¢â‚¬Å¡Ãƒâ€šÃ‚Â¬ÃƒÆ’Ã†â€™Ãƒâ€šÃ‚Â¢ÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€¦Ã‚Â¾ÃƒÆ’Ã¢â‚¬Å¡Ãƒâ€šÃ‚Â¢s valuation of Fidson Healthcare Limited reveals a fair value of N5.22 for each Ordinary share of the company (including the shares to be freshly issued). This therefore implies that the Private Placement price of N3.95 is being offered at a marked discount of 24.3% to valuation.